The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives
Authors:
- Tjerk BuetersTBTjerk Bueters
- Bart A. PloegerBPBart A. Ploeger
- Sandra A.G. VisserSVSandra A.G. Visser
- 1 September 2013
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 18 (17-18) , 853-862
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- What is the most important approach in current drug discovery: doing the right things or doing things right?Drug Discovery Today, 2012
- Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survivalDrug Discovery Today, 2012
- Diagnosing the decline in pharmaceutical R&D efficiencyNature Reviews Drug Discovery, 2012
- Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and developmentDrug Discovery Today, 2011
- Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and DevelopmentPharmaceutical Research, 2011
- How to improve R&D productivity: the pharmaceutical industry's grand challengeNature Reviews Drug Discovery, 2010
- On Setting the First Dose in Man: Quantitating Biotherapeutic Drug‐Target Binding through Pharmacokinetic and Pharmacodynamic ModelsBasic & Clinical Pharmacology & Toxicology, 2010
- Planning for ReductionAlternatives to Laboratory Animals, 2009
- In Vitro Methods for Estimating Unbound Drug Concentrations in the Brain Interstitial and Intracellular FluidsDrug Metabolism and Disposition, 2007
- Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling: Biophase Distribution, Receptor Theory, and Dynamical Systems AnalysisAnnual Review of Pharmacology and Toxicology, 2007